PharmExec roundtable w/Pfizer, AstraZeneca, Merck&Co and Regeneron

Email this to someoneShare on LinkedInTweet about this on TwitterShare on FacebookShare on Google+
Pharma Exec

Two words define the future of commercialization and project management: Faster and Better

One remedy for hard times that is uniquely within biopharma companies’ own sphere of control is finding better ways to manage internal operations and processes that produce products.

Project and process engineering is attracting more attention from the “c-suite,” and it’s time to declare process innovation in drug development and commercialization as a strategic capability—when done well, it can spell all the difference in launching a new product, between life cycle hegemony and that hardly-worth-a-ripple “ho hum.”
To shed light on what works and what doesn’t, William Looney, Editor-in-Chief at PharmExec convened four big Pharma practitioners of the art of commercial effectiveness to discuss what makes their days a constant challenge in turning a world of multiplying left-field risks into manageable routines.